A

Abzena

CDMO for complex biologics and ADCs

Process Engineer 2/Senior

Full-TimeUpdated on 10/23/2026
No salary listed
Senior
Bristol, PA, USA
In PersonOnsite in Bristol, Pennsylvania.
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • At least 6 years of experience within biopharmaceutical, biologics, bioconjugation, antibody-drug conjugate, or contract development and manufacturing organization manufacturing environments.
  • Demonstrated experience independently supporting Good Manufacturing Practice manufacturing operations and leading complex process engineering activities.
  • Strong experience with technology transfer, process scale-up, process troubleshooting, data analysis, and process optimization.
  • Experience leading process validation support, engineering studies, manufacturing investigations, and change implementation.
Responsibilities
  • Provide advanced process engineering support for Good Manufacturing Practice manufacturing operations, including bioconjugation, chromatography, filtration, formulation, and single-use processing systems.
  • Provide on-floor technical leadership during manufacturing campaigns, including complex troubleshooting, technical decision support, and issue resolution.
  • Partner with Manufacturing and Manufacturing Science and Technology teams to improve process robustness, throughput, yield, scalability, and execution efficiency.
  • Lead technical investigations related to process deviations, operational issues, and adverse process performance trends, including root cause analysis and corrective action development.
  • Develop and implement process improvements and engineering solutions that enhance operational reliability and reduce recurring manufacturing risk.
  • Lead or serve as the Process Engineering technical lead for technology transfer activities from Process Development into Good Manufacturing Practice Manufacturing.
  • Lead process scale-up assessments, equipment fit evaluations, engineering studies, and manufacturing readiness planning.
  • Review and provide technical approval or input for manufacturing records, protocols, technical documents, and process instructions to ensure readiness and technical accuracy.
  • Lead or provide technical oversight for process validation, process performance qualification activities, engineering runs, and process characterization studies.
  • Serve as a senior technical resource and mentor to Process Engineers and manufacturing personnel.
  • Coach less experienced engineers in troubleshooting, technical writing, investigation methodology, and Good Manufacturing Practice engineering practices.
  • Promote accountability, collaboration, Good Manufacturing Practice compliance, technical rigor, and continuous improvement across engineering activities.
  • Independently prioritize complex engineering work and support the Senior Manager in coordinating technical activities aligned with manufacturing schedules and site objectives.
  • Ensure assigned engineering activities comply with current Good Manufacturing Practice regulations, internal procedures, and company quality standards.
  • Lead or provide senior technical support for deviations, corrective and preventive actions, investigations, change controls, and risk assessments related to process engineering.
  • Participate in regulatory inspections and client audits as a technical subject matter expert and support preparation of technical responses.
  • Drive improvements that reduce repeat deviations, strengthen process consistency, and improve technical control of manufacturing processes.
  • Analyze process performance metrics, equipment utilization, manufacturing trends, and process capability to identify improvement opportunities.
  • Lead Lean and continuous improvement initiatives focused on process efficiency, waste reduction, throughput, and manufacturing effectiveness.
  • Develop and implement standardized engineering practices, technical tools, and operational improvements across manufacturing operations.
  • Collaborate with Operations leadership to improve schedule adherence, campaign execution reliability, and technical readiness.
  • Partner closely with Manufacturing, Manufacturing Science and Technology, Quality, Supply Chain, Facilities and Engineering, and Program Management teams.
  • Support and, when appropriate, lead client-facing technical discussions related to manufacturing execution, investigations, process performance, and improvement plans.
  • Provide technical leadership in campaign planning, operational readiness reviews, and production support activities.
  • Identify and escalate significant technical risks, operational constraints, and process concerns to the Senior Manager, Process Engineering with recommended actions.
Desired Qualifications
  • Experience serving as a technical subject matter expert during regulatory inspections or client audits.
  • Experience within bioconjugation, antibody-drug conjugate, oligonucleotide, or complex biologics manufacturing environments.
  • Contract development and manufacturing organization experience supporting external clients.
  • Experience supporting startup operations or facility expansions.
  • Lean Six Sigma or continuous improvement experience.

About the company

Abzena is a CDMO that provides integrated services for complex biologics and bioconjugates, including antibody-drug conjugates (ADCs). It supports projects from antibody discovery through GMP manufacturing for clinical trials and commercial supply, using its in-house platforms and expertise. It differentiates itself with end-to-end development and manufacturing capabilities, supported by proprietary technologies like ThioBridge and Composite Human Antibody, and global facilities in San Diego, Bristol, and Cambridge. Its goal is to help biologics programs progress efficiently from discovery to market by offering specialized, partnered development and manufacturing services and potential licensing of its technologies.

Company Size

201-500

Company Stage

IPO

Headquarters

Babraham, United Kingdom

Founded

2001

Get referred to Abzena

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • March 2026 Frost recognized Abzena as an ADC CDMO leader.
  • September 2025 GS knockout CHO-K1 platforms expanded AbzelectPRO capabilities.
  • 2026 AOC momentum, including Novartis-Avidity and Dyne, lifts demand for integrated services.

What critics are saying

  • Headcount fell 6.4% from 2023 to March 2026, signaling operational tightening.
  • WCAS ownership creates exit pressure, distracting management from long-term customer retention.
  • Large pharma can internalize ADC manufacturing, leaving Abzena dependent on fragile biotech demand.

What makes Abzena unique

  • Abzena spans discovery, conjugation, and GMP manufacturing across San Diego, Bristol, and Cambridge.
  • ThioBridge and integrated ADC expertise distinguish Abzena in complex bioconjugates.
  • Its 2026 Frost Radar leadership validates specialization in ADCs and AOCs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget

Growth & Insights and Company News

6 month growth

0%

1 year growth

-1%

2 year growth

-1%
Abzena
Jul 15th, 2026
Outsourced Pharma capability Update - Cell Line Development June 2026.

Outsourced Pharma capability Update - Cell Line Development June 2026. Early cell line decisions define everything that comes after: yield, stability, manufacturability, and timelines. That's why Abzena PLC presented at the Outsourced Pharma Capabilities Update on June 16th, which is focused on Cell Line Development strategies. Abzena's VP & Scientific Leader of Cell Line Development, John E. Gill IV, presented a talk on "Integrated Cell Line Development: Manufacturability to GMP-Ready by Design." John broke down how a truly integrated approach, one built with GMP readiness and manufacturability in mind from day one, changes the trajectory of complex biologic programs. The result: - Accelerated timelines to GMP - Reduced downstream risk - Cell lines engineered to meet GMP standards, not retrofitted to them - A smoother, faster path from discovery to clinical & commercial manufacturing When GMP readiness is designed in from the start, not added later, programs don't stall. They move forward faster.

Abzena
Mar 17th, 2026
Frost radar report: Antibody-Drug Conjugate contract development & manufacturing organizations.

Frost radar report: Antibody-Drug Conjugate contract development & manufacturing organizations. Abzena is recognized as a technology-forward, innovative CDMO in the Frost radar(tm): ADC contract development and manufacturing report, 2025. In this comprehensive analysis of the Antibody-Drug Conjugate (ADC) contract development and manufacturing (CDMO) market, global research analysts Frost & Sullivan, an independent firm, evaluated leading service providers and recognized Abzena as a Leader in both Innovation and Growth. As the author of the report, Unmesh Lal, VP of Healthcare & Life Sciences at Frost & Sullivan, shared, "With deep analytical expertise, flexible licensing models, and a dual US-UK footprint, Abzena combines scientific rigor with commercial agility. Its 'grow-with-the-client' strategy is converting early-stage partnerships into long-term manufacturing relationships, solidifying its position as a premier end-to-end CDMO for complex biologics." * How Abzena's proprietary ThioBridge(R) site-specific conjugation platform improves the design & delivery of ADCs. * How a fully integrated end-to-end development and manufacturing model eliminates tech-transfer risks and reduces timelines & costs. * How assay development for complex ADC & AOC characterization provides the data needed to de-risk clinical programs & build confidence with regulators and investors * How a dual US and UK integrated footprint provides a secure supply chain and deep FDA and EMA regulatory expertise.

Clinical Research News
Sep 16th, 2025
Abzena Enhances AbZelectPRO(TM) Cell Line Offering with New GS Knockout Platforms

Abzena enhances abzelectpro(tm) cell line offering with new GS knockout platforms san diego, CA - september 15, 2025 - abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced the expansion of its abzelectpro(tm) cell line development (CLD) platform with the launch of two next-generation glutamine synthetase ("GS") knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins.

Bio-IT World
Jul 22nd, 2025
Appointment; Abzena Appoints Geoffrey M. Glass as Chief Executive Officer

San Diego, CA - July 22, 2025 - Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, today announced that Geoffrey M. Glass has been appointed Chief Executive Officer (CEO), effective immediately.

PR Newswire
May 15th, 2025
Abzena Announces Establishment Of Scientific Advisory Board To Support Innovation Strategy

SAN DIEGO, May 15, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today the formation of its Scientific Advisory Board (SAB) comprised of biopharma industry experts with diversified expertise in Discovery Research & Development (R&D) and Chemistry, Manufacturing, and Controls (CMC). The new advisory board will work closely with Abzena's scientific and commercial leadership to provide strategic guidance and expert insights that support Abzena's continued commitment to growth and innovation.Matt Stober, CEO of Abzena, said, "The establishment of the Scientific Advisory Board was a strategic decision to help guide the future of Abzena. We have seen considerable momentum over the past few years in supporting complex and innovative modalities, such as Antibody-drug conjugates (ADCs), Antibody-oligonucleotide conjugates (AOCs), and bispecifics. We aim to continue building upon this by offering the most state-of-the-art technologies and capabilities to support our customers' programs. These experts will be instrumental in assisting us with this mission by evaluating our strategies and providing recommendations that will further enhance our ability to move medicines forward to patients faster."Joe Principe, CCO of Abzena, said, "We are honored to welcome these distinguished individuals to our Scientific Advisory Board. These founding members are recognized leaders in our industry, bringing a wealth of expertise that will help guide us as we continue through this significant phase of our growth